According to reports, celecoxib inhibits NF-kB by boosting the IkB inhibitor protein, lowering blood levels of CXCL5, and blocking the AKT/NF-kB pathway that is involved in cancer and angiogenesis [46]. Here, CXCL5 is linked to cancer.